Free Trial

Soleno Therapeutics (SLNO) News Today

Soleno Therapeutics logo
$54.83 +3.04 (+5.87%)
(As of 11/20/2024 ET)
Soleno Therapeutics Reports Q3 Progress and Financials
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics (NASDAQ:SLNO) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Soleno Therapeutics in a research note on Monday.
Cantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)
Soleno Therapeutics, Inc. stock logo
Harbor Capital Advisors Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Harbor Capital Advisors Inc. purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 36,048 shares of the company's stock, valued at approximately $1,82
Soleno Therapeutics, Inc. stock logo
Emerald Advisers LLC Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Emerald Advisers LLC raised its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 313,334 shares of the company's stock after buying an additio
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Recommendation of "Buy" by Analysts
Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy ra
Soleno Therapeutics price target raised to $73 from $65 at Oppenheimer
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month High on Analyst Upgrade
Soleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year High on Analyst Upgrade
Soleno Therapeutics announces passing of former chairman Ernest Mario
10 Biggest Stocks with Negative Beta to Consider
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics (NASDAQ:SLNO) Trading 6.4% Higher - Still a Buy?
Soleno Therapeutics (NASDAQ:SLNO) Trading 6.4% Higher - Time to Buy?
Soleno Therapeutics, Inc. stock logo
The Manufacturers Life Insurance Company Raises Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
The Manufacturers Life Insurance Company lifted its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 120.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,408 shares of the company's st
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics Target of Unusually Large Options Trading (NASDAQ:SLNO)
Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock traders bought 11,478 put options on the stock. This represents an increase of approximately 1,203% compared to the average daily volume of 881 put options.
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High - Still a Buy?
Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month High - Here's Why
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of "Buy" by Analysts
Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to
Soleno Therapeutics, Inc. stock logo
Kristen Yen Sells 3,108 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock
Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Kristen Yen sold 3,108 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total value of $153,628.44. Following the completion of the transaction, the insider now directly owns 81,465 shares in the company, valued at approximately $4,026,814.95. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Position Raised by Nantahala Capital Management LLC
Nantahala Capital Management LLC raised its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 27.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,082,107 shares of the company's stock after purchasing an ad
Soleno Therapeutics, Inc. stock logo
Perceptive Advisors LLC Raises Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Perceptive Advisors LLC boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,204,976 shares of the company's stock after acquir
Soleno Therapeutics, Inc. stock logo
Samlyn Capital LLC Purchases 282,122 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Samlyn Capital LLC lifted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 128.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 501,049 shares of the company's stock a
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Lifted by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC grew its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 28.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,091,666 shares of the company
Soleno Therapeutics, Inc. stock logo
Rhumbline Advisers Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Rhumbline Advisers purchased a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 29,144 shares of the company's stock, valued at approximately $1,189,000. Rhumbl
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics' (SLNO) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Soleno Therapeutics in a report on Friday.
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 52-Week High at $54.32
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High at $54.32
Soleno Therapeutics, Inc. stock logo
Sofinnova Investments Inc. Raises Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Sofinnova Investments Inc. increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 267.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 554,359 shares of the company's stock afte
Soleno Therapeutics, Inc. stock logo
Bank of New York Mellon Corp Acquires Shares of 88,799 Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Bank of New York Mellon Corp bought a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 88,799 shares of the company's stock, valued at approximately $3,623,000. Bank of New Yor
Soleno Therapeutics, Inc. stock logo
Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume
Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume
Soleno Therapeutics, Inc. stock logo
TD Asset Management Inc Boosts Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)
TD Asset Management Inc boosted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 174.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,534 shares of the company's stock a
Get Soleno Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

SLNO Media Mentions By Week

SLNO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SLNO
News Sentiment

0.00

0.45

Average
Medical
News Sentiment

SLNO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SLNO Articles
This Week

1

3

SLNO Articles
Average Week

Get Soleno Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SLNO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners